TheDigger Intelligence Unit
A new experimental drug may help in the fight against fatty liver disease, which is quickly becoming a major global health problem.
For 52-year-old Maria Gomez, diagnosed with MASH two years ago, hope has been hard to come by. “Every doctor told me to lose weight, but nothing seemed to stop my liver from getting worse,” she shared.
Now, scientists at the University of California, San Diego, have introduced ION224, offering new optimism.
This treatment targets fat buildup in the liver, a main cause of metabolic dysfunction-associated steatohepatitis (MASH).
Most current treatments focus on weight loss or lifestyle changes, but these are often difficult to sustain and not always effective.
ION224 works differently by blocking DGAT2, an enzyme that helps make and store fat in the liver. By stopping this process at a molecular level, the drug lowers both inflammation and scarring.
For patients like Maria, this means the possibility of halting the disease before it leads to cirrhosis, liver failure, or cancer—a hope that previous therapies have struggled to deliver.
A Phase IIb clinical trial included 160 adults with MASH. Those who got the highest dose of ION224 showed significant improvements; about 60% had better liver health compared to those who took a placebo.
The drug also worked for people who did not lose much weight, addressing a key limitation of previous treatments. Most people tolerated ION224 well, with few serious side effects. Researchers hailed the findings, published in The Lancet, as the first clear evidence that blocking DGAT2 with antisense therapy can improve liver inflammation and fibrosis.
“By interrupting fat accumulation and inflammation at the source, we may finally halt and even reverse liver damage,” said Dr Rohit Loomba, principal investigator of the study. Dr. Anna Patel, a liver specialist not involved in the trial, commented, “If these results hold up in larger studies, ION224 could change the way we treat MASH and related conditions.”
MASH, which used to be called NASH, is part of a larger condition known as MASLD.
It is closely linked to obesity and type 2 diabetes and affects over 100 million Americans—many of whom are unaware they have it.
Globally, as many as one in four adults may suffer from MASH. The disease often progresses silently, causing little to no symptoms until serious, sometimes irreversible, liver damage has occurred.
For people like Maria, early intervention with a drug like ION224 could mean the difference between maintaining a normal life and facing a liver transplant.
The next step for ION224 is to test it in larger Phase III trials, which will determine if the drug is safe and effective in a broader population.
These studies will also examine how ION224 could be combined with existing weight-loss drugs or metabolic treatments—potentially offering a multipronged approach to battling fatty liver disease.
However, challenges remain, including the need for long-term safety data, regulatory approval, and ensuring the drug will be accessible and affordable to patients worldwide.
Still, for millions at risk of serious liver disease, the promise of a new treatment has never been brighter.